1Schiller JH,Harrington D,Belani CP,et al Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346:92 -8 被引量：1
2Harma N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versous docetaxel in patients with non-smallcell lung cancer previously treated with chemotherary [J].J Clin Oncol 2004 ;22:1589 - 97 被引量：1
3Fuknoka M,Yano S,Giaccone G,et al .Multi-institutiional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL I Trial)[J]J Clin Oncol,2003,21 (12) :2237 -46 被引量：1
4Sandler AB,Gray R,Brahmer J,et al.Randomized phase Ⅱ / Ⅲ trial of paclitaxel(P) plus carboplatin(C) with or without bevacizumab (NSE#704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) :An Eastern Cooperative Oncology Group(ECOG) Trial-E4599 [J].Proc Am Soc Clin Oncol,2005,23:2 (Abstr LBA4) 被引量：1
2Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology [J] . Cancer Metasta Rev, 1993, 12 (3-4) :303-324. 被引量：1
3Vaziri SA, Kim J, Ganapathi MK, et al. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors [J] . Curr Oncol Rep, 2010, 12 (2) : 102~108. 被引量：1
